https://scholars.lib.ntu.edu.tw/handle/123456789/465723
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Tsai M.-H. | en_US |
dc.contributor.author | Pan C.-H. | en_US |
dc.contributor.author | Peng C.-L. | en_US |
dc.contributor.author | MING-JIUM SHIEH | en_US |
dc.creator | Tsai M.-H.;Pan C.-H.;Peng C.-L.;Ming-Jium Shieh | - |
dc.date.accessioned | 2020-02-27T06:39:24Z | - |
dc.date.available | 2020-02-27T06:39:24Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2192-2640 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018564185&doi=10.1002%2fadhm.201700111&partnerID=40&md5=f075918f98a68cfafb17969e5089a355 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/465723 | - |
dc.description.abstract | Targeted combination chemotherapy (TCT) has recently been used to increase the induction of tumor cell death. In particular, the combination of Panitumumab and the platinum (Pt)-derived chemotherapeutic drug Oxaliplatin is clinically effective against KRAS and BRAF wild-type colorectal cancer (CRC) cells that overexpress epidermal growth factor receptors, and significantly greater efficacy is observed than with either drug alone. However, low accumulation of Pt drug in tumor sites prevents achievement of ideal efficacy. To develop an alternative drug therapy that achieves the ideal efficacy of TCT, the novel nanomedicine NANOPt-Pan using self-assembled dichloro(1,2-diaminocyclohexane)Pt(II)-modified Panitumumab is generated. Treatments with NANOPt-Pan lead to significant accumulation of Pt drug and Panitumumab in tumors, reflecting enhanced permeability and retention effect, active targeting, and sustained circulation of the Pt drug in the blood. In addition, NANOPt-Pan has excellent in vivo anti-CRC efficacy. These data indicate that NANOPt-Pan has high potential as a candidate nanomedicine for CRC. ? 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim | - |
dc.publisher | Wiley-VCH Verlag | - |
dc.relation.ispartof | Advanced Healthcare Materials | - |
dc.subject | colorectal cancer; combination therapy; Oxaliplatin; Panitumumab | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | Cell death; Chemotherapy; Diseases; Medical nanotechnology; Tumors; Colorectal cancer; Colorectal cancers (CRC); Combination chemotherapy; Combination therapy; Enhanced Permeability and Retention effect; Epidermal growth factor receptors; Oxaliplatin; Panitumumab; Platinum compounds; 1,2 diaminocyclohexane; antineoplastic metal complex; coordination compound; dichloro(1,2 diaminocyclohexane) platinum; NANOplatinum panitumumab; oxaliplatin; panitumumab; unclassified drug; antineoplastic agent; drug carrier; monoclonal antibody; nanoparticle; oxaliplatin; panitumumab; platinum complex; animal experiment; animal model; antineoplastic activity; Article; Caco-2 cell line; colorectal cancer; controlled study; cytotoxicity; drug accumulation; drug conjugation; drug efficacy; drug penetration; drug retention; drug targeting; female; HT-29 cell line; human; human cell; in vivo study; molecularly targeted therapy; mouse; nanomedicine; nonhuman; priority journal; animal; chemistry; colorectal tumor; drug screening; metabolism; pathology; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Colorectal Neoplasms; Drug Carriers; Female; Humans; Mice; Nanomedicine; Nanoparticles; Organoplatinum Compounds; Xenograft Model Antitumor Assays | - |
dc.title | Panitumumab-Conjugated Pt-Drug Nanomedicine for Enhanced Efficacy of Combination Targeted Chemotherapy against Colorectal Cancer | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1002/adhm.201700111 | - |
dc.identifier.pmid | 28418176 | - |
dc.identifier.scopus | 2-s2.0-85018564185 | - |
dc.relation.journalvolume | 6 | - |
dc.relation.journalissue | 13 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Biomedical Engineering | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | School of Medicine | - |
crisitem.author.orcid | 0000-0003-2921-4443 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Engineering | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學工程學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。